lifestyle.luxedb.com

Author: BioVersys

BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100

April 16, 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

April 15, 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)

April 13, 2026
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health

March 31, 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025

March 18, 2026
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start

March 16, 2026
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis

March 12, 2026
BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call

March 5, 2026
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy

March 4, 2026
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine

February 19, 2026